Top Stories
BMS Scores First Phase 3 Win for CELMoD Mezigdomide in Multiple Myeloma
Bristol Myers Squibb announced positive interim results from the SUCCESSOR-2 phase 3 trial (NCT05552976), in which oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) met the primary endpoint of progression-free survival in relapsed/refractory multiple myeloma patients, according to Fierce Biotech and the company's press release. The Cereblon E3 ligase modulator (CELMoD) represents BMS's effort to extend its myeloma franchise beyond Revlimid and Abecma. The trial tested MeziKd versus carfilzomib and dexamethasone alone (Kd), demonstrating statistically significant and clinically meaningful PFS improvement. Safety findings were consistent with the known profile of mezigdomide and the combination regimen. BMS plans to present full data at a future medical meeting and share results with health authorities. The CELMoD class works by degrading specific proteins via the ubiquitin-proteasome system, offering differentiation from traditional immunomodulatory drugs. BMS adds a third-generation option to its myeloma portfolio at a time when Revlimid faces biosimilar erosion. The company has positioned mezigdomide for earlier lines of therapy and combination strategies. Watch for full data presentation at an upcoming hematology congress to assess magnitude of PFS benefit and whether overall survival trends emerge.
Roche Oral SERD Giredestrant Fails Pivotal First-Line Breast Cancer Trial
Roche disclosed that giredestrant, an oral selective estrogen receptor degrader (SERD) it had positioned as a potential multi-billion-dollar franchise, failed to meet its primary endpoint of progression-free survival in the persevERA Breast Cancer phase 3 trial (NCT04546009) for first-line ER-positive, HER2-negative locally advanced or metastatic breast cancer, per Fierce Biotech and Roche's press release. The trial enrolled 992 patients and tested giredestrant plus palbociclib versus letrozole plus palbociclib. While a numerical PFS improvement was observed, it did not reach statistical significance. Adverse events were manageable and consistent with the known safety profiles of each agent. TD Cowen analysts had previously suggested the adjuvant success in the lidERA trial strongly implied a first-line win, making this miss unexpected. Roche's first-line ambitions for giredestrant face significant setback, challenging the multi-billion-dollar revenue narrative analysts had built around the oral SERD. Despite the miss, the FDA recently accepted a New Drug Application for giredestrant based on evERA data in the advanced pretreated setting, and Roche plans to submit lidERA adjuvant data to the FDA in the coming weeks. A second first-line study, pionERA, testing giredestrant in endocrine-resistant disease is expected to read out in 2027.
FDA Grants Priority Review for Enhertu in HER2-Positive Early Breast Cancer
The FDA accepted for priority review Daiichi Sankyo and AstraZeneca's supplemental biologics license application for Enhertu (trastuzumab deruxtecan) as post-neoadjuvant treatment in HER2-positive early breast cancer patients with residual invasive disease, according to PharmExec and the companies' joint press release. The application is based on the DESTINY-Breast05 phase 3 trial, which showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus trastuzumab emtansine (T-DM1), with a hazard ratio of 0.47 (p<0.0001). Three-year invasive disease-free survival reached 92.4% with Enhertu versus 83.7% with T-DM1. The PDUFA target action date is July 7, 2026. The sBLA is being reviewed under Project Orbis and also received Breakthrough Therapy Designation in December 2025. This would mark Enhertu's entry into curative-intent treatment after approvals in metastatic breast, gastric, and lung cancers. Early-stage breast cancer represents a substantially larger patient population than metastatic settings, with nearly 16,000 US patients treated annually in the post-neoadjuvant setting. Daiichi Sankyo and AstraZeneca position Enhertu to dominate HER2-positive breast cancer across all lines of therapy. The approval would directly challenge Roche's Kadcyla in the post-neoadjuvant setting where T-DM1 currently holds standard-of-care status. Enhertu also reduced distant recurrence risk by 51% and brain metastasis risk by 36% versus T-DM1, suggesting meaningful impact on metastatic progression patterns.
Pipeline Watch
The National Cancer Institute began recruiting patients for a study testing cabozantinib added to chemotherapy in newly diagnosed high-grade localized osteosarcoma, per ClinicalTrials.gov (NCT05691478). The trial represents an effort to improve outcomes in a rare pediatric cancer where standard chemotherapy regimens have not meaningfully advanced in decades. Cabozantinib targets VEGFR and MET pathways implicated in osteosarcoma progression. Watch for enrollment milestones and interim futility analyses in 2027.
Uppsala University opened enrollment for a phase 3 trial evaluating abbreviated immunotherapy duration after radical surgery in high-risk melanoma patients, according to ClinicalTrials.gov (NCT06488482). The study tests whether shorter treatment courses maintain efficacy while reducing toxicity and cost. Current adjuvant immunotherapy typically runs 12 months with checkpoint inhibitors like nivolumab or pembrolizumab. If successful, the trial could redefine standard duration and impact payer coverage decisions globally. Data readout expected late 2028 based on event-driven design.
Roche transitioned its master protocol evaluating multiple targeted therapies in non-small cell lung cancer (NCT03178552) to active non-recruiting status per ClinicalTrials.gov. The umbrella trial tested various Roche investigational agents across biomarker-defined NSCLC subsets. The status change suggests enrollment completion with follow-up ongoing for survival endpoints. Roche has not disclosed which arms within the trial met futility or efficacy thresholds. Expect selective data presentations at ASCO 2026 for arms that showed clinical promise.
Competitive Landscape
The FDA priority review for Enhertu in HER2-positive early breast cancer sets up a direct challenge to Roche Kadcyla which holds dominant share in the post-neoadjuvant setting, according to PharmExec and the AstraZeneca/Daiichi Sankyo press release. Daiichi Sankyo and AstraZeneca position to capture majority share given DESTINY-Breast05 superiority data showing a 53% reduction in invasive disease recurrence or death. Roche faces margin pressure as Kadcyla loses exclusivity in a setting that generates approximately $1.8B annually. The curative-intent indication also de-risks Enhertu long-term growth as metastatic populations face competitive threats from bispecifics.
| Drug | Setting | Status | Est Annual Sales |
|---|---|---|---|
| Enhertu | Post-Neoadjuvant | Priority Review | $4B+ potential |
| Kadcyla | Post-Neoadjuvant | Standard of Care | $1.8B current |
Bristol Myers Squibb's first phase 3 success for mezigdomide in the SUCCESSOR-2 trial extends its myeloma franchise runway as Revlimid faces biosimilar competition generating roughly 40% revenue declines year-over-year, per Fierce Biotech and the BMS press release. The CELMoD mechanism offers differentiation versus Johnson & Johnson talquetamab and Regeneron linvoseltamab bispecifics that target GPRC5D and BCMA respectively. BMS maintains pole position in a $15B global myeloma market through 2030. Competitive dynamics will depend on mezigdomide's ability to move into earlier treatment lines where J&J and Regeneron lack Phase 3 data.
The persevERA Breast Cancer trial failure marks a setback for the oral SERD class after Roche bet heavily on giredestrant as a first-line ER-positive breast cancer option, per Fierce Biotech and the Roche press release. The giredestrant-palbociclib combination could not demonstrate statistically significant PFS benefit over letrozole-palbociclib despite a numerical improvement. Jefferies analysts said the result challenges the multi-billion-dollar narrative that had rebuilt around giredestrant after adjuvant and second-line wins. The first-line oral SERD class faces credibility questions as the lead program in the largest addressable setting stumbles. Roche retains a path forward through the pionERA first-line endocrine-resistant trial (readout 2027), the evERA-based NDA under FDA review, and the upcoming lidERA adjuvant submission. AstraZeneca's camizestrant and Eli Lilly's imlunestrant remain the closest oral SERD competitors.
Forward Looking
- Watch for BMS to present full SUCCESSOR-2 mezigdomide Phase 3 data including hazard ratios and subgroup analyses at an upcoming hematology congress to assess commercial positioning of MeziKd versus J&J and Regeneron bispecifics in relapsed/refractory myeloma.
- Expect Roche to provide strategic update on giredestrant following the persevERA first-line miss, likely emphasizing the evERA-based NDA under FDA review, the upcoming lidERA adjuvant submission, and the pionERA endocrine-resistant trial readout expected in 2027.
- Monitor Enhertu label language when FDA issues approval decision by July 7, 2026 PDUFA date, particularly whether agency restricts use to patients with residual disease post-neoadjuvant or allows broader adjuvant monotherapy claims that would expand addressable population.
- Track Uppsala University melanoma trial enrollment pace to gauge physician willingness to randomize high-risk patients to shorter immunotherapy duration, as slow accrual could indicate community skepticism and delay practice-changing data by 12-18 months.